Status:
TERMINATED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Colon Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cancers of the colon and rectum are the third most common cancers in Canadian males and females. The initial therapy of colorectal cancer is surgery to remove the cancer and nearby lymph glands. If th...
Detailed Description
Hypothesis: Recently, the thymidylate synthase gene's promoter has been found to be polymorphic, with variable numbers of tandem repeats of 28 base pairs in length. These polymorphisms have been asso...
Eligibility Criteria
Inclusion
- High risk Stage II or III colon cancer
- Eastern Cooperative Oncology Group performance status (ECOG P.S.) O or l
- No prior chemotherapy
- Complete tumor resection
- Candidate for and planned to receive standard capecitabine
- Adequate bone marrow reserve
Exclusion
- Known DED deficiencies
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 11 2019
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT00126867
Start Date
May 1 2005
End Date
April 11 2019
Last Update
July 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2